Projects per year
Fingerprint
Dive into the research topics where Klaus Podar is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
JAK2 inhibitors: JAK2 inhibitors and the innate immune response in mutant CALR-driven MPNs
Stoiber-Sakaguchi, D. (PI), Podar, K. (CoPI) & Kollmann, K. (CoPI)
Gesellschaft für Forschungsförderung NÖ
01.01.2022 → 31.12.2026
Project: Funded Research
-
APOG: ACCESS POINT Oncology
Podar, K. (PI), Stoiber-Sakaguchi, D. (CoPI), Pecherstorfer, M. (CoPI), Georg, P. (CoPI), Kieseberg, P. (CoPI), Fossati, P. (CoPI), Lütgendorf-Caucig, C. (CoPI) & Slade, D. (CoPI)
01.01.2020 → 31.12.2026
Project: Funded Research
-
STAT3: STAT3 isoforms in hematopoietic disorders
Stoiber-Sakaguchi, D. (PI), Podar, K. (CoPI) & Casanova, E. (CoPI)
Gesellschaft für Forschungsförderung NÖ
01.01.2021 → 31.12.2024
Project: Funded Research
-
PROTACs : Targeting Transcription factors for cancer therapy utilizing PROteolysis-TArgeting Chimera (PROTACs)
Podar, K. (PI)
01.08.2020 → 31.10.2022
Project: Forschungsimpulse › Research Time Out (RTO)
-
Biomarker: Biomarker- based therapeutic prevention of bone metastases in breast cancer. Defining the pathophysiologic impact of the endosteal niche
Vallet, S. (PI), Podar, K. (CoI) & Wiesner, C. (CoPI)
Gesellschaft für Forschungsförderung NÖ
01.12.2019 → 31.12.2023
Project: Funded Research
Research output
-
Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia
Weiss, S., Zdársky, B., Witalisz-Siepracka, A., Edtmayer, S., Holzer, A., Heindl, K., Casanova, E., Podar, K. & Stoiber, D., 31 Mar 2025, In: Cancer Letters. 613, p. 217501 217501.Research output: Journal article (peer-reviewed) › Journal article
Open Access -
Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapy
Meli, R., Aksoy, O., Vallet, S., Slade, D. & Podar, K., 2025, In: Expert Opinion on Therapeutic Targets. 29, 3, p. 101-115 15 p.Research output: Journal article (peer-reviewed) › Journal article
-
Cure for multiple myeloma?
Podar, K., May 2025, In: Memo - Magazine of European Medical Oncology. 18, 2, p. 108-115 8 p.Research output: Journal article (peer-reviewed) › Review article
Open Access1 Citation (Scopus) -
Novel extended quadruplet induction regimens—challenging the need for upfront high-dose therapy in newly diagnosed all-risk multiple myeloma patients
Podar, K., 07 Apr 2025, In: AME Clinical Trials Review .Research output: Journal article (peer-reviewed) › Review article
-
PARP7 as a new target for activating anti-tumor immunity in cancer
Popova, K., Benedum, J., Engl, M., Lütgendorf-Caucig, C., Fossati, P., Widder, J., Podar, K. & Slade, D., 14 May 2025, In: EMBO Molecular Medicine. 17, 5, p. 872-888 17 p., 108176.Research output: Journal article (peer-reviewed) › Review article
Open Access3 Citations (Scopus)